Patient Square Capital’s EyePoint EYPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-720,000
Closed -$10.3M – 27
2026
Q2
$10.3M Sell
720,000
-75,000
-9% -$1M 1.6% 18
2026
Q1
$10.2M Buy
795,000
+15,000
+2% +$224K 1.82% 15
2025
Q4
$14.3M Sell
780,000
-231,839
-23% -$3.29M 3.05% 8
2025
Q3
$14.4M Sell
1,011,839
-340,998
-25% -$3.93M 3.85% 3
2025
Q2
$12.7M Sell
1,352,837
-129,140
-9% -$892K 4.59% 4
2025
Q1
$8.03M Buy
1,481,977
+71,646
+5% +$501K 3.32% 4
2024
Q4
$10.5M Buy
1,410,331
+48,352
+4% +$450K 3.93% 5
2024
Q3
$10.9M Buy
+1,361,979
New +$12M 4.04% 5

Other funds holding EYPT

Patient Square Capital's EYPT Position: Q3 2026 in Review

Patient Square Capital sold out of EyePoint (EYPT) in Q3 2026, closing a stake of 720,000 shares — an estimated $10.3M sold.

Patient Square Capital first reported a position in EYPT in Q3 2024 and held it in 8 quarters. The position peaked at $14.4M in Q3 2025. 190 funds tracked by Wall St. Rank hold EYPT as of Q3 2026.

  • Patient Square Capital reported no remaining EyePoint position as of Q3 2026 after selling out during the quarter.
  • Patient Square Capital sold 720,000 EyePoint shares in Q3 2026, an estimated $10.3M.
  • Patient Square Capital first reported a position in EyePoint in Q3 2024 and held it in 8 quarters.
  • Patient Square Capital's EyePoint position peaked at $14.4M in Q3 2025.
  • 190 funds tracked by Wall St. Rank held EyePoint as of Q3 2026.

Based on Patient Square Capital's 13F filing for Q3 2026, filed 10 Nov 2026.